Zobrazeno 1 - 10
of 19
pro vyhledávání: '"A B Colowick"'
Autor:
A B Colowick, N S Tchekmedyian, G. Rossi, Glen R. Justice, S Armstrong, J. Jadeja, J Kessler, J O'Byrne, John A. Glaspy, D Richards, Lee S. Schwartzberg
Publikováno v:
British Journal of Cancer
British journal of cancer, vol 87, iss 3
British journal of cancer, vol 87, iss 3
In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g. kg−1 wk−1 or to a control group receiving epoetin alfa at an initial dose of 150 U kg−1 three times weekly. In part B, the coh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a25a1cc10e213daf4707f1a43bc274dc
https://doi.org/10.1038/sj.bjc.6600465
https://doi.org/10.1038/sj.bjc.6600465
Autor:
J Singh Jadeja, A Saven, D Gordon, A B Colowick, J Kessler, D Richards, J O'Byrne, George D. Demetri, J Rigas, David C. Harmon, Ralph V. Boccia, H Hynes, G Justice, D Prow, John A. Glaspy, J Arseneau, David J. Kuter, Lee S. Schwartzberg
Publikováno v:
British Journal of Cancer. 84:17-23
Darbepoetin alfa is a novel erythropoiesis stimulating protein (NESP), which stimulates erythropoiesis by the same mechanism as recombinant human erythropoietin (rHuEPO). NESP has been shown to be safe and efficacious in patients with chronic renal f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf9cb2234bf5dd3f26605ffbd4d5fb74
https://doi.org/10.1054/bjoc.2001.1748
https://doi.org/10.1054/bjoc.2001.1748
Autor:
M Rarick, U Gayko, L A Meza, I A Jaiyesimi, S Brosman, N S Tchekmedyian, A B Colowick, M Murdoch, D Chan, John A. Glaspy, Ronald M. Bukowski, A Saven, H Griffith, R E Smith, Alex Fleishman
Publikováno v:
British Journal of Cancer
Anaemia is a common haematologic disorder in patients with cancer and has a multifactorial aetiology, including the effects of the malignancy itself and residual effects from previous therapy. Novel erythropoiesis stimulating protein (NESP, darbepoet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eead186334ee2709ce5598e8758476c
http://europepmc.org/articles/PMC2363901
http://europepmc.org/articles/PMC2363901
Publikováno v:
Blood. 96:1698-1702
The development of inhibitory antibodies to factor VIII (FVIII) occurs in approximately 30% to 40% of patients with severe hemophilia A. Management options for patients with inhibitor include eradicating it via immune tolerance induction (ITI) or tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aedaf22c040f77e0b076b75e19cfbd2
https://doi.org/10.1182/blood.v96.5.1698.h8001698_1698_1702
https://doi.org/10.1182/blood.v96.5.1698.h8001698_1698_1702
Autor:
D Chan, G. Rossi, R E Smith, Donald W. Northfelt, N S Tchekmedyian, R Patel, M. Austin, A B Colowick, John A. Glaspy, L A Meza
Publikováno v:
British Journal of Cancer
A multicentre study evaluated the efficacy and safety of darbepoetin alpha administered weekly (QW), every 3 weeks (Q3W), and every 4 weeks (Q4W) to anaemic patients with cancer not concurrently receiving chemotherapy or radiotherapy. The QW portion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9c2e7a0381b75adcf86bc48ce6a648b
https://pubmed.ncbi.nlm.nih.gov/12799626
https://pubmed.ncbi.nlm.nih.gov/12799626
Publikováno v:
Cancer. 97(5)
BACKGROUND Anemia in patients receiving chemotherapy can be ameliorated with recombinant human erythropoietin (rHuEPO), which is administered one to three times per week. Darbepoetin α, a new erythropoietic agent, has longer serum residence time, al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f7930e737f92a20241786fb03faa05
https://pubmed.ncbi.nlm.nih.gov/15042691
https://pubmed.ncbi.nlm.nih.gov/15042691
Autor:
Barry, Mirtsching, Veena, Charu, Saroj, Vadhan-Raj, Alan B, Colowick, Gregory, Rossi, Dianne, Tomita, William P, McGuire
Publikováno v:
Oncology (Williston Park, N.Y.). 16(10 Suppl 11)
The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 microg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by pooling data from three darbepoe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::813fecccbf16ed75212942b7cdff08e1
https://pubmed.ncbi.nlm.nih.gov/12435171
https://pubmed.ncbi.nlm.nih.gov/12435171
Publikováno v:
Blood. 96(5)
The development of inhibitory antibodies to factor VIII (FVIII) occurs in approximately 30% to 40% of patients with severe hemophilia A. Management options for patients with inhibitor include eradicating it via immune tolerance induction (ITI) or tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ff34e8ba761b3857dfb1866f7ce5ef1
https://pubmed.ncbi.nlm.nih.gov/10961866
https://pubmed.ncbi.nlm.nih.gov/10961866
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 5(6)
Economic analyses in haemophilia care are at present limited, but are increasingly being used to examine the costs and outcomes associated with various treatment regimens. The assignment of probabilities and costs in these models can be challenging,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::987c42f4248b358aac8e20b138623070
https://pubmed.ncbi.nlm.nih.gov/10583522
https://pubmed.ncbi.nlm.nih.gov/10583522
Autor:
A.M. Garin, A. B. Colowick, Tudor Ciuleanu, G.T. Tidmarsh, György Bodoky, A.V. Pavlovsky, Stewart Kroll, V. K. Langmuir
Publikováno v:
European Journal of Cancer Supplements. 5:260-261
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::191c3e9b60fac29dc4c26b622a9d454b
https://doi.org/10.1016/s1359-6349(07)71008-x
https://doi.org/10.1016/s1359-6349(07)71008-x